News from Tuesday, October 1, 2024
Articles
New Analysis Points to Troubling Trends as U.S. Healthcare Costs Rise, but Health Outcomes Worsen
(10/1, Heather Landi, Fierce Healthcare) reports “...In the U.S., national health expenditures increased from $2.8 trillion in 2012 to $4.5 trillion in 2022, despite relatively little change in demand or utilization, and are projected to grow to $7.7 trillion by 2032...[Chief research officer Sanjula Jain, Ph.D.] says the trends outlined in Trilliant Health's analysis should serve as a ‘wake-up call’ to the healthcare industry to focus on ‘value for money.’” Full
UK: Roche’s Injectable C5 Inhibitor PiaSky Recommended by NICE for Rare Blood Disorder PNH
(10/1, Emily Kimber, PMLiVE) reports “Roche’s injectable component C5 inhibitor has been recommended by the National Institute for Health and Care Excellence to treat the rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH).” Full
EU HTA Regulation: Views Wanted On Draft Rules On Joint Scientific Consultations
(10/1, Francesca Bruce, Pink Sheet) reports “...A newly published draft implementing act sets out the procedural rules for the joint scientific consultations that are foreseen by the EU’s Health Technology Assessment Regulation.” Subscription Required
Press Releases
Study Provides Estimates of CMS Initial Price Offers for First 10 High-Spend Brands
(10/1, ISPOR Press Release) “...‘Our analysis sheds light on important price benchmarks and clinical evidence factors for the determination of the initial price offers,’ explained author Sean D. Sullivan, PhD, Professor, The CHOICE Institute, School of Pharmacy, University of Washington, Seattle, Washington, USA. ‘While we were not able to simulate the offer and counter-offer process, our findings provide a transparent and systematic way to estimate initial price offers that are consistent with CMS guidance.’” Full
NICE Ready to Work with Company to Address Uncertainty in Evidence for Elacestrant for Advanced Breast Cancer
(10/1, NICE News Release) “...The draft guidance, which is open for public consultation until 22 October, does not recommend elacestrant for treating oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer with an activating ESR1 mutation...We have asked the company for further clarification and analyses ahead of the committee’s next meeting on 12 November.” Full
Journals
Low-Dose Triple-Pill vs Standard-Care Protocols for Hypertension Treatment in Nigeria: A Randomized Clinical Trial
Dike B. Ojji, PhD, et al.
August 31, 2024, JAMA
Balloon Angioplasty vs Medical Management for Intracranial Artery Stenosis: The BASIS Randomized Clinical Trial
Xuan Sun, MD, et al.
September 5, 2024, JAMA
FOUNTAIN: A Modular Research Platform for Integrated Real-World Evidence Generation
Nikolaus G. Oberprieler, et al.
October 1, 2024, BMC Medical Research Methodology